دورية أكاديمية
The role of new hepatitis B vaccines in South Africa.
| العنوان: | The role of new hepatitis B vaccines in South Africa. |
|---|---|
| المؤلفون: | Van Zyl GU; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa. guvz@sun.ac.za., Maponga T; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa. tongai@sun.ac.za., Rabie H; Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Tygerberg Children's Hospital, Cape Town, South Africa. hr@sun.ac.za., Taljaard J; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Tygerberg Academic Hospital, Cape Town, South Africa. jjt@sun.ac.za. |
| المصدر: | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde [S Afr Med J] 2024 Feb 13; Vol. 114 (2), pp. e1473. Date of Electronic Publication: 2024 Feb 13. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: South African Medical Association Country of Publication: South Africa NLM ID: 0404520 Publication Model: Electronic Cited Medium: Internet ISSN: 2078-5135 (Electronic) NLM ISO Abbreviation: S Afr Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1998- : Cape Town : South African Medical Association Original Publication: Cape Town : Medical Association of South Africa, |
| مواضيع طبية MeSH: | Hepatitis B*/epidemiology , Hepatitis B*/prevention & control , Diabetes Mellitus* , HIV Infections*/epidemiology , HIV Infections*/prevention & control, Infant ; Child ; Adult ; Humans ; Middle Aged ; Hepatitis B Vaccines ; Hepatitis B Surface Antigens ; South Africa/epidemiology ; Hepatitis B virus ; Vaccination |
| مستخلص: | Vaccination is key to eliminating hepatitis B virus infection in South Africa (SA). Despite introducing immunisation in 1995, as part of the expanded programme of immunisation (EPI), hepatitis B virus infection remains endemic, and EPI vaccine coverage is incomplete. In addition to infants, non-immune adults at risk of infection through their occupation or with behavioural risk factors should receive vaccination. SA has many individuals with diabetes mellitus (a prevalence of almost 13%), obesity, HIV (8.45 million) or older age (5 million >60 years old), associated with a poorer vaccine response. Recently two new hepatitis B vaccines have been licensed: HEPLISAV-B includes an adjuvant that improves immunogenicity and has shown improved vaccine response in individuals with HIV, old age or diabetes mellitus. PreHevbrio, which includes three hepatitis B surface protein domains, instead of one, may also be more immunogenic, although clinical study data are still limited. These two novel vaccines have not yet been investigated in children and licensed in SA. Should HEPLISAV-B become available in SA, it may be particularly valuable to target high-risk groups in the country, such as people living with HIV, who show a poor response to the currently licensed vaccine. |
| المشرفين على المادة: | 0 (Heplisav-B) 0 (Hepatitis B Vaccines) 0 (Hepatitis B Surface Antigens) |
| تواريخ الأحداث: | Date Created: 20240325 Date Completed: 20240326 Latest Revision: 20240326 |
| رمز التحديث: | 20240326 |
| DOI: | 10.7196/SAMJ.2024.v114i2.1473 |
| PMID: | 38525577 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2078-5135 |
|---|---|
| DOI: | 10.7196/SAMJ.2024.v114i2.1473 |